Role of the microvascular endothelium in progressive renal disease

Journal of the American Society of Nephrology

Volumn 13, Issue 3, 2002, Pages 806-816

  Kang, Duk Hee ^a   Kanellis, John ^a   Hugo, Christian ^a   Truong, Luan ^a   Anderson, Sharon ^a   Kerjaschki, Dontscho ^a   Schreiner, George F ^a   Johnson, Richard J ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; ANGIOPOIETIN; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOSTATIN; GROWTH FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; OSTEONECTIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROSTAGLANDIN E2; SCATTER FACTOR; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASOACTIVE AGENT;

ANGIOGENESIS; BLOOD PRESSURE; CELL PROLIFERATION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; ENDOTHELIUM CELL; GLOMERULUS; GLOMERULUS CAPILLARY; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY SCAR; MACROPHAGE ACTIVATION; MEDIATOR RELEASE; MICROVASCULARIZATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0036191166     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. A simple method of estimating progression of chronic renal failure
2. The progression of renal disease
3. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease
4. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats
5. Cycloxygenase-2 in the kidney
6. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney
7. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model
8. Transforming growth factor-beta in tissue fibrosis
9. Evidence for a central role of glomerular growth promoters in the development of glomerulosclerosis
10. Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation, and apoptosis
11. Progressive renal failure-inability of podocytes to replicate and the consequences for development of glomerulosclerosis
12. Apoptosis in glomerular sclerosis
13. Role of increased glomerular protein traffic in the progression of renal failure
14. Role of cellular infiltrates in response to proteinuria
15. The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: The glomerular cytokine theory
16. Macrophages in renal injury
17. Evolution of tubulointerstitial fibrosis in experimental renal infection and scarring
18. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats
19. Apoptosis and renal scarring
20. Progressive renal disease: The chronic hypoxia hypothesis
21. Physiology of renal hypoxia
22. Cyclosporin A increases hypoxia and free radical production in rat kidneys: Prevention by dietary glycine
23. Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity
24. Hypoxia promotes fibrogenesis in human renal fibroblasts
25. Therapeutic effect of converting enzyme inhibition in progressive renal disease
26. Understanding the nature of renal disease progression
27. Angiotensin II receptors in the kidney. Localization and physiological significance
28. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy
29. Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin
30. Morphometry of the renal corpuscle during normal postnatal growth and compensatory hypertrophy; a light microscope study
31. Compensatory growth of glomeruli is accomplished by an increased number of glomerular capillaries
32. Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis
33. Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant kidney model
34. Impaired angiogenesis in the aging kidney: Potential role of VEGF and TSP- 1 in renal disease
35. Impaired angiogenesis in the remnant kidney model (I): Potential role of vascular endothelial growth factor and thrombospondin-1
36. Significance of post-glomerular capillaries in the pathogenesis of chronic renal failure
37. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: Altered expression of vascular endothelial growth factor
38. Tubulointerstitial disease in aging: Evidence for peritubular capillary damage. A potential role for renal ischemia
39. Peritubular capillary injury during the progression of experimental glomerulonephritis in rats
40. Role of vascular endothelial growth factor in the regulation of angiogenesis
41. Thrombospondin 1 and type 1 repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells
42. Thrombospondins
43. Thrombospondin cooperates with CD 36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis
44. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system
45. Thrombospondin 1, a TGF-β activating protein, precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease
46. Thrombospondin 1 is the key activator of TGF-β 1 in human mesangial cells exposed to high glucose
47. Thrombospondin I is expressed by proliferating mesangial cells in vivo and is regulated by PDGF and bFGF
48. Aging-associated changes in renal extracellular matrix
49. Sustained expression of thrombospondin 1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model
50. SPARC (BM- 40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells
51. SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits PDGF-mediated mesangial cell proliferation in vitro
52. SPARC is expressed in renal interstitial fibrosis and in renal vascular injury
53. SPARC gene expression is reduced in early diabetes related growth
54. Induction of TGF-β by the matricellular protein SPARC in a rat model of glomerulonephritis
55. SPARC regulates the expression of collagen type I and transforming growth factor-beta 1 in mesangial cells
56. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain
57. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165
58. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway
59. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
60. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease
61. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells
62. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
63. VEGF is required for growth and survival in neonatal mice
64. Vascular endothelial growth factor is an essential molecule for mouse kidney development
65. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney
66. Vascular permeability factor (VEGF) gene is expressed differentially in normal tissues, macrophages, and tumors
67. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy
68. Glypican- 1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165
69. Expression of vascular endothelial growth factor and its receptors in rats with protein overload nephrosis
70. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts
71. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases
72. Neovascularization in aged mice: Delayed angiogenesis is coincident with decreased levels of transforming growth factor beta 1 and type I collagen
73. Macrophages and angiogenesis
74. Macrophages from inflamed but not normal glomeruli are unresponsive to anti-inflammatory cytokines
75. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1
76. Changes in renal micro- and macrovasculature induced by inhibition of nitric oxide synthesis in the remnant kidney model: New mechanism for progression of renal disease
77. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis
78. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells
79. Participation of the glomerular endothelial cell in capillary repair in glomerulonephritis
80. Vascular endothelial growth factor (VEGF165) mediates glomerular endothelial repair
81. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis
82. 121) protects rats from renal infarction in a model of hemolytic uremic syndrome
83. A new model of renal microvascular endothelial injury
84. The C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis
85. Impaired angiogenesis in the remnant kidney model (II): VEGF administration reduces renal fibrosis and stabilizes renal function
86. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes
87. Vascular endothelial growth factor and diabetes: The agonist versus antagonist paradox
88. Angiogenesis in autosomal-dominant polycystic kidney disease
89. Proliferation and remodeling of the peritubular microcirculation after nephron reduction. Association with the progression of renal lesions
90. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Podoplanin as a specific marker of lymphatic endothelium
91. Angiogenesis in cancer, vascular, rheumatoid and other disease
92. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes